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Abstract: The utility of [18F]WC-4-116, a PET tracer for imaging caspase-3 activation, was evaluated in an animal 
model of myocardial apoptosis. [18F]WC-4-116 was injected into rats at 3 hours after a 30 min period of ischemia 
induced by temporary occlusion of the left anterior descending coronary artery in Sprague-Dawley rats. [18F]WC-
4-116 uptake was quantified by 1) autoradiography, 2) microPET imaging studies, and 3) post-PET biodistribution 
studies. MicroPET imaging also assessed uptake of the non-caspase-3-targeted tracer [18F]ICMT-18 at 3 hours post-
ischemia. Enzyme assays and Western blotting assessed caspase-3 activation in both at-risk and not-at-risk regions. 
Caspase-3 enzyme activity increased in the at-risk but not in the not-at-risk myocardium. Quantitative autoradio-
graphic analysis of [18F]WC-4-116 demonstrated nearly 2-fold higher uptake in the ischemia-reperfusion (IR) versus 
sham animals. [18F]WC-4-116 microPET imaging studies demonstrated that the IR animals was similarly elevated 
in relation to sham. [18F]ICMT-18 uptake did not increase in at-risk myocardium despite evidence of caspase-3 ac-
tivation. Biodistribution studies with [18F]WC-4-116 confirmed the microPET findings. These data indicate that the 
caspase-3-PET tracer [18F]WC-4-116 can noninvasively image in vivo caspase activity during myocardial apoptosis 
and may be useful for clinical imaging in humans.
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Introduction
Apoptosis is a highly regulated, adenosine tri-
phosphate (ATP)-dependent cellular death pro-
gram that plays a crucial role during embryonic 
development, maintenance of the immune sys-
tem, and tissue homeostasis [1]. Two indepen-
dent pathways can mediate this process. 
Stimuli such as ischemia-reperfusion (IR) injury 
activate the intrinsic apoptotic pathway that 
involves mitochondrial permeabilization lead-
ing to cytochrome c release and caspase-9 
activation. In contrast, cytokines and other fac-
tors such as the Fas ligand or tumor necrosis 
factor-alpha bind to external cell receptors to 
activate the extrinsic pathway, leading to cas-
pase-8 activation. Both caspase-8 and cas-
pase-9 lead to activation of the executioner 
caspases, caspase-3 and -7. These latter cas-
pases are responsible for mediating the hall-
mark physiologic and morphologic cellular 
changes of cells undergoing apoptosis; specifi-
cally, cytoplasmic and nuclear condensation, 
DNA fragmentation, membrane blebbing, as 
well as phosphatidylserine (PS) externalization 
on the outer leaflet of the plasma membrane [2, 
3]. These pathways as they relate to imaging 
have been recently reviewed [4].
Over the past decade, dysregulated apoptosis 
has been implicated in a wide spectrum of clini-
cally important diseases [5, 6]. The importance 
of apoptotic cell death in cardiovascular dis-
ease is also increasingly being recognized. 
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Increased cardiomyocyte apoptosis has been 
noted in ischemic and non-ischemic cardiomy-
opathies, atherosclerosis, and cardiac allograft 
rejection [7-10]. Following prolonged myocardi-
al ischemia, cardiomyocyte necrosis predomi-
nates. However, with timely reperfusion, 
increased levels of apoptosis have been detect-
ed [11, 12], at which time caspase inhibition 
may preserve myocytes, reducing infarct size 
and potentially protecting cardiac function [13, 
14]. Thus, noninvasive means of detecting 
apoptosis in vivo may be useful tools for assess-
ing the degree of apoptosis both to assess for 
potential intervention efficacy and to study the 
factors that contribute to increased apoptosis 
vs necrosis [15, 16].
A number of approaches have been developed 
to image apoptosis in vivo [4]. However, most of 
these methods do not measure apoptosis spe-
cifically. SPECT- and PET-based tracers have 
targeted annexin V, a 37 kDA protein that binds 
to externalized phosphatidylserine (PS) resi-
dues expressed only on apoptotic cells [17-19], 
but these tracers can also detect PS residues 
in necrotic cells as a results of cell membrane 
breakdown [20]. The targeting specificity of 
both radiolabeled amphipathic small molecule 
PET tracers, like [18F]ML-10 [21], and the MRI 
agent superparamagnetic iron oxide (SPIO)-
labeled synaptogamin, for apoptotic cells [22] 
has also been questioned. Therefore, radiola-
beled small-molecule PET imaging agents that 
bind to more apoptosis-specific targets will 
potentially improve upon these existing imaging 
approaches.
Isatin sulfonamide analogs are potent inhibi-
tors of caspase-3 and -7 [23] that have been 
radiolabeled for PET imaging [24]. Initial 
microPET imaging studies have shown that 
these analogs readily detect both hepatic and 
chemotherapy-induced tumor apoptosis [25-
27]. [18F]WC-4-116 is a second generation 
radiolabeled isatin sulfonamide analogue with 
enhanced potency for the executioner caspas-
es (~4.5 nM and ~3.8 nM for caspase-3 and -7 
respectively [24]. Given the importance of 
apoptosis in cardiac disease, we sought to 
assess the ability of [18F]WC-4-116 to image 
caspase-3/7 activity as a marker of ischemia-
induced apoptosis using a modified version of a 
well-characterized rat cardiac ischemia-reper-
fusion model induced by left anterior descend-
ing (LAD) ligation [28]. 
Materials and methods
Synthesis of [18F]WC-4-116 and [18F]ICMT-18
The tracers [18F]WC-4-116 and [18F]ICMT-18 
were synthesized from the corresponding 
alkyne precursors as previously published [25, 
29, 30]. The radiosynthetic scheme for [18F]
WC-4-116 is shown in Figure 1. Briefly, a 
solution of alkyne precursor in DMF was 
added to a solution 2-[18F] fluoroethyl azide, 
synthesized and distilled in t-amyl alcohol, 
followed by the addition of a mixture of 
CuSO4·5H2O and sodium ascorbate in water. 
The reaction mixture was allowed to react at 
room temperature for 10 min, and standard 
solid phase extraction methods were used to 
remove t-amyl alcohol and other salts. The 
tracer was purified by reversed phase HPLC. 
All radiolabeling was done manually. The iso-
lated yields from the radiosynthesis were typi-
cally 20-30% (not decay-corrected), with radio-
chemical purity >99%, and specific activity 
of 1-2 Ci/μMol. In vitro caspase inhibition by 
[18F]ICMT-18 was confirmed using previously 
described methods that are detailed in the 
Figure 1. Radiosynthesis scheme for [18F]WC-4-116.
Imaging caspase-3 activity following IR injury
112 Am J Nucl Med Mol Imaging 2016;6(2):110-119
supplement [31]. Cell uptake studies conduct-
ed as previously described [24] and detailed 
in the supplement also confirmed [18F]WC-4-
116 specificity for binding caspase-3. 
Animal groups, in vivo LAD coronary artery 
ligation, and myocardial tissue harvest
All animal procedures were conducted in accor-
dance with guidelines published in the Guide 
for the Care and Use of Laboratory Animals 
and were approved by the Animal Studies 
Committee of the Washington University School 
of Medicine. Temporary ligation of the LAD or 
sham surgery was performed on male Sprague-
Dawley rats (9-11 weeks of age, 275-300 g, 
Charles River Laboratories) as previously 
described [32]. During the procedure, the 
suture passed under the LAD was tied for 30 
min to induce ischemia followed by release to 
allow reperfusion (ischemia-reperfusion, IR, 
group) or left in place without tying for the sham 
surgeries (SS group). Immediately after the 
suture was released to restore perfusion, the 
chest was closed. Following the surgical proce-
dure, the animals were weaned from ventilator 
support with reversal agent (atipamezole, 1 
mg/kg SC) administered to hasten recovery.
For myocardial tissue harvest, animals were 
reanesthetized with 1-2% isoflurane at 3 hours 
after ligation, and the thorax was reopened to 
tie off the LAD, producing distal blanching. 
Evan’s Blue dye (5% in saline; Sigma-Aldrich) 
was injected via tail vein to delineate the myo-
cardial at-risk region. The hearts were quickly 
excised, the unstained at-risk and stained not 
at-risk myocardium were separated, snap-fro-
zen in liquid nitrogen, and stored at -80°C for in 
vitro analysis. Caspase-3 activation was con-
firmed at 3 hours after reperfusion (i.e. 3 hours 
after release of the tied suture, N = 5 IR group, 
N = 3 SS group) using the methods described 
below (Supplemental Figure 1). This time point 
was thus used for all tracer studies. Myocardial 
tissue was also obtained from the animals 
used for autoradiography (N = 3 per group) and 
microPET imaging experiments (N = 4 per group 
except for N = 3 in the IR group imaged with 
[18F]ICMT-18).
Fluorometric assay and western immunoblot-
ting for caspase-3/7 activity and expression. 
Caspase-3/7 activity was assayed in the at-risk 
and not at-risk myocardial samples as previ-
ously published [27]. In brief, 200 mg of protein 
from homogenized myocardial tissue in the 
presence or absence of caspase-3/7 inhibitor 
(1 mM Ac-DEVD-CHO; Sigma-Aldrich) was incu-
bated in assay buffer containing caspase-3/7 
substrate (20 mM AC-DVED-AMC; Biomol 
International). Fluorescence was measured 
every hour for 8 hr, plotted, and linear regres-
sion applied to determine the rate of caspase-3 
activity in units of amido-4-methylcoumarin 
(AMC) produced per min per mg protein.
For caspase-3 western immunoblotting, 100 
µg of protein was subjected to SDS-PAGE 
using 4-15% Tris-HCl for ~90 min at 100 V fol-
lowed by the protein transfer to Immobilon P 
membrane (Millipore, Inc). After blocking with 
5% milk in Tris-buffered saline for 1 hr, the 
membrane was probed with anti-caspase-3 pri-
mary antibody (1:1000; Cell Signaling) over-
night at 4°C, washed, blotted with peroxidase-
conjugated secondary antibody (1:10,000), 
washed, then developed (SuperSignal West 
Dura, Thermo Scientific). 
Ex vivo autoradiography with [18F]WC-4-116 
and [18F]ICMT-18
After the 3 hr reperfusion interval, IR and 
SS animals (N = 3 per group) were injected 
with ~1-1.5 mCi of [18F]WC-4-116 or [18F]ICMT-
18 via tail vein under isoflurane anesthesia. 
Myocardial tissue, harvested as described 
above, was sliced in 1 mm axial sections and 
measured over 80 minutes for autoradiograph-
ic determination of tracer distribution (Packard 
InstantImager). Corresponding photographic 
images of these stained sections were then 
obtained using a flatbed scanner (Hewlett 
Packard). The accumulated regional radioactiv-
ity of the at-risk and not at-risk regions, 
expressed as a ratio of the counts in the 
at-risk vs not-at-risk regions (counts/mm2at-risk: 
counts/mm2f) was determined for animals in 
each treatment group. 
MicroPET imaging protocol 
The animals were anesthetized with 1-2% iso-
flurane and imaged with an Inveon microPET/
CT scanner (Siemens, Knoxville, TN). After 
obtaining CT images for attenuation correction, 
the dynamic PET acquisition started at five sec-
onds after tracer injection. A 10-minute dynam-
ic microPET image acquisition with [15O]H2O 
Imaging caspase-3 activity following IR injury
113 Am J Nucl Med Mol Imaging 2016;6(2):110-119
(500-700 µCi) to quantify myocardial blood flow 
(MBF) was performed followed by a 30 min 
dynamic acquisition with either [18F]WC-4-116 
or [18F]ICMT-18 (400-500 µCi). Following 
microPET imaging, the at-risk and not at-risk 
regions were excised as described above for 
gamma counting and caspase-3 activity 
assessment. Images were reconstructed using 
a fast maximum a posteriori (fastMAP) algo-
rithm implemented by Siemens Inc with a 
CT-based attenuation correction. The following 
frame binning schedule was used in the recon-
struction: 24 × 5 sec, 8 × 60 sec, 6 × 180 sec, 
and 4 × 300 sec. 
Image analysis and quantification
The left-ventricle blood pool (LVBP) was local-
ized by summing early frames (typically the first 
10 frames) of [18F]WC-4-116 or [18F]ICMT-18 
images (see Supplemental Figure 2 for blood 
pool images). A region of interest (ROI) was 
drawn on LVBP and overlaid onto [15O]H2O imag-
es to reconstruct the arterial input function 
form activity in the reference region, LV, and RV 
with high signal only in the at-risk region. For 
this reason, we chose to display the data as the 
ratio of standard uptake value (SUV) of at-risk 
to not-at-risk regions. The myocardial blood flow 
(MBF) in the at-risk region of each imaged ani-
mal was quantified by optimizing a mathemati-
cal model for [15O]H2O [34].
Biodistribution studies
Tracer biodistribution in the myocardium was 
further confirmed for all animals undergoing 
microPET imaging. After completing the micro-
PET imaging session, the at-risk and not at- 
risk myocardium were harvested, weighed, 
and immediately frozen on dry ice. These sec-
tions were counted separately by Beckman 
Gamma 8000 well counter while frozen and 
then later assayed for caspase-3 enzyme 
activity (as above). The percent-injected dose 
per gram of tissue (%ID/g) was determined for 
each sample and %ID/gat-risk: %ID/gnot at-risk was 
determined for each treatment.
Figure 2. Autoradiography of IR and SS animals administered the tracers [18F]
WC-4-116 or [18F]ICMT-18 and representative Evan’s Blue stained cardiac 
sections (A) Quantitation of tracer accumulation from autoradiography stud-
ies (counts/mm2) of the at-risk and not at-risk myocardial regions are shown 
graphically (B). Bonferroni-adjusted p-values for pair-wise comparisons are 
indicated.
[33]. Similarly, the at-risk 
region of the LV myocardium 
was identified adjacent to 
LVBP from the sum of the 
last 10 min of imaging with 
[18F]WC-4-116 (Supplemental 
Figure 2). Because the left 
ventricular wall could not be 
visualized with [18F]ICMT-18, 
the LVBP images were used 
as a reference to place ROIs 
in a similar location as with 
the [18F]WC-4-116 images to 
correspond to the ventricular 
wall. A region in the superior 
half of the LV wall represent-
ing the not at-risk myocardi-
um was identified in a similar 
manner. ROIs circumscribing 
these respective areas were 
utilized to generate time-
activity curves for at-risk and 
not at-risk regions respective-
ly. We observed significant 
spill-over from both the right 
and left ventricles (RV and LV, 
respectively) into the refer-
ence region, in particular at 
early time points. At late time 
points, however, there is uni-
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Statistical methods
Differences in at-risk myocardial caspase-3/7 
activity for model validation studies between IR 
and SS treatments were analyzed using the 
two-sided Student’s t-test as were differences 
in mean SUV or %ID/g between groups. For all 
other data, a two-way ANOVA analysis with 
interaction was conducted to identify the 
effects of tracer and treatment on at-risk myo-
cardial caspase-3/7 activity, at-risk myocardial 
blood flow, SUVat-risk: SUVnot at-risk, %ID/gat-risk: %ID/
gnot at-risk from animals undergoing microPET 
imaging and counts/mm2at-risk: counts/mm
2
not at-
risk derived from the autoradiography studies. 
Significance was identified at the alpha level of 
5% (α = 0.05) for all statistical analyses. A sig-
nificant interaction indicates that the effect of 
treatment on the index varies with respect to 
tracer (or vice-versa). Following a significant 
interaction, post-hoc analyses were conducted 
testing all pair-wise comparisons of tracer and 
treatment combinations. Bonferroni-adjusted 
post-hoc results were reported. All analysis was 
conducted in SAS® v9.3 (SAS Institute, Inc., 
Cary, NC).
Results
In vitro studies and model validation
The inability of [18F]ICMT-18 to inhibit cas-
pase-3 activation was confirmed in vitro 
(Supplemental Figure 3). Staurosporine treated 
HeLa cells demonstrated increased [18F]WC-4-
116 uptake that was blocked up to 50% or 
greater with cold WC-4-116 (Supplemental 
Figure 4).
Autoradiography studies 
Autoradiography demonstrated substantial 
[18F]WC-4-116 accumulation localized to the at-
risk myocardium as demarcated by dye staining 
(Figure 2A). In contrast, no significant accumu-
lation of [18F]WC-4-116 was seen with SS treat-
ment (Figure 2B). Cardiac sections from ani-
mals administered [18F]ICMT-18 demonstrated 
no significant accumulation in the unstained 
Figure 3. MicroPET imaging of IR and SS animals with the tracers [18F]WC-4-116 and [18F]ICMT-18. (A) Structure 
of [18F]WC-4-116. (B) Structure of [18F]ICMT-18. (C-F) Representative late summed microPET images of IR and SS 
animals imaged with [18F]WC-4-116 (C, D) or [18F]ICMT-18 (E, F). [18F]WC-4-116 microPET imaging demonstrates LV 
tracer uptake in IR (panel C) but not SS animals (D). Images of IR (E) and SS (F) animals administered [18F]ICMT-18 
demonstrate no focal myocardial accumulation of this tracer. White boxes denote cardiac position; white arrowhead 
indicates LV uptake. 
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ventricular at-risk region in the IR, which 
appeared similar to that seen in the SS animals 
without any at-risk myocardium. 
[18F]WC-4-116 accumulation, based on autora-
diographic quantitation of regional tracer accu-
mulation expressed as counts/mm2at-risk: 
counts/mm2not at-risk was significantly higher in IR 
than SS animals (2.05 ± 0.17 versus 1.00 ± 
0.01; p < .001), shown in Figure 2B. No differ-
ence was found in [18F]ICMT-18 uptake between 
the IR and SS animals (1.06 ± 0.02 and 1.02 ± 
0.05 respectively, p = 1.00). The difference in 
counts/mm2at-risk: counts/mm
2
not at-risk between 
IR and SS was also greater for [
18F]WC-4-116 
than for [18F]ICMT-18 (p < 0.001).
In vivo detection of myocardial apoptosis with 
[18F]WC-4-116 microPET imaging studies
Representative late summed images from 30 
min dynamic microPET imaging studies of IR 
and SS animals administered [18F]WC-4-116 or 
[18F]ICMT-18 are shown in Figure 3. As observed 
with autoradiography, microPET images of IR 
animals imaged with [18F]WC-4-116 demon-
strated tracer accumulation in the LV free wall 
corresponding to the at-risk IR myocardial zone 
that was not observed in the SS group (Figure 
3). While more nonspecific binding was seen 
diffusely when [18F]ICMT-18 imaging was per-
formed, neither IR nor SS animals showed trac-
ICMT-18 in at-risk and not-at-risk myocardium 
did not differ between IR and SS animals, yield-
ing SUVat-risk: SUVnot at-risk ratios that near unity 
(Figure 4). SUVat-risk: SUVnot at-risk ratios for [
18F]
WC-4-116 were significantly higher than those 
for [18F]ICMT-18 in at-risk myocardial tissue (p = 
0.002 for interaction). Representative time-
activity curves from the microPET imaging stud-
ies are shown in Supplemental Figure 5.
Post-microPET biodistribution studies
In the [18F]WC-4-116 imaging groups, the %ID/g 
of the at-risk myocardial samples from the IR 
animals was more than twice that of the SS ani-
mals (0.14 ± 0.01 versus 0.05 ± 0.01; p < 
0.05). In contrast, the accumulated radioactiv-
ity content of the not at-risk myocardium from 
these two treatments was not statistically dif-
ferent (0.07 ± 0.01 versus 0.05 ± 0.01; p = 
0.28). Accordingly, %ID/gat-risk: %ID/gnot at-risk was 
significantly higher in IR vs SS animals (p = 
0.003; Figure 5). The %ID/g of the at-risk and 
not-at-risk myocardium for SS and IR animals 
undergoing [18F]ICMT-18 microPET were both 
higher relative to that measured with [18F]WC-4-
116; however, %ID/gat-risk: %ID/gnot at-risk for these 
experimental groups did not differ (p = 1.00). 
The difference in %ID/gat-risk: %ID/gnot at-risk 
between IR and SS was significantly greater for 
[18F]WC-4-116 and [18F]ICMT-18 (p = 0.003).
Figure 4. SUV analysis of microPET images. Mean SUV of the at-risk and 
not at-risk myocardial regions of the experimental imaging groups were mea-
sured and the mean ratio of SUVat-risk: SUVnot at-risk (± standard error) was de-
rived. All treatments are n = 4 except for the IR group imaged with [18F]ICMT-
18 (n = 3) with a p-value (ANOVA) = 0.002 for interaction between tracer and 
treatment type. Bonferroni-adjusted p-values for pair-wise comparisons are 
indicated.
er accumulation in the at-risk 
LV myocardium when com-
pared with IR animals imaged 
with [18F]WC-4-116. 
SUV analysis of the late 
summed images from the 
dynamic microPET scans of 
the four groups confirmed the 
visual assessment of the 
images. The average SUV of 
the at-risk LV region for [18F]
WC-4-116 was higher than 
the not-at-risk myocardium in 
IR animals (0.81 versus 0.46, 
respectively; p = 0.012) but 
not in SS animals (0.49 at-risk 
versus 0.51 not-at-risk; p = 
0.92). SUVat-risk: SUVnot at-risk (i.e. 
SUVtarget: SUVreference) for the IR 
animals was significantly 
higher than in SS animals. 
The average SUVs for [18F]
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Ex vivo analysis of myocardial caspase-3/7 
The caspase-3 activity of the at-risk LV myocar-
dium in all IR animals imaged by microPET 
increased compared to SS animals (Figure 6), 
confirming the results from the validation stud-
ies (shown in Supplemental Figure 1). 
Discussion
Isatin sulfonamide analogues are potent, mem-
brane-permeable inhibitors of caspases [23]. 
mately 2-fold increase in [18F]WC-4-116 accu-
mulation when comparing at-risk to not-at-risk 
myocardium. We used immunoblotting studies 
as well as measurements of caspase-3 activity 
using a standard fluorometric enzyme assay to 
assess the degree of caspase-3 activation in 
at-risk myocardium where [18F]WC-4-116 accu-
mulates in this model. These assays confirmed 
that caspase-3 activation occurred only in 
areas where [18F]WC-4-116 accumulated. Thus, 
these data support our hypothesis that [18F]
Figure 5. Biodistribution studies. %ID/g of the at-risk and not at-risk myocar-
dial samples derived from the experimental imaging groups was measured 
and the mean ratio of %ID/gat-risk: %ID/gnot at-risk (± standard error) was derived. 
All treatments are n = 4 except for the SS group imaged with [18F]ICMT-18 
(n = 3) with a p-value (ANOVA) = 0.003 for interaction between tracer and 
treatment type. Bonferroni-adjusted p-values for pair-wise comparisons are 
indicated.
Figure 6. Ex vivo analysis of at-risk myocardial caspase-3/7 activity of IR and 
SS animals undergoing tracer microPET imaging. Mean caspase-3/7 activity 
(± standard error) of the at-risk ventricular samples isolated from the ex-
perimental imaging groups was measured by ex vivo fluorometric assay. All 
treatments are n = 4 with a p-value (ANOVA) = 0.033 for interaction between 
tracer and treatment type. Bonferroni-adjusted p-values for pair-wise com-
parisons are indicated.
We and others have devel-
oped radiolabeled isatin sul-
fonamide analogues with 
enhanced specificity for the 
executioner caspases and 
greater membrane permea-
bility [24, 25, 35]. Thus, these 
tracers have the advantage of 
targeting enzymes that are 
specifically activated by the 
apoptotic cascade, unlike 
other approaches which may 
image apoptosis but will also 
likely image cells dying 
by necrosis as well [17-19]. 
These functionalized small 
molecules have been utiliz- 
ed as tracers for microPET 
imaging studies detecting in 
vivo apoptosis in chemothera-
py-, cycloheximide-, and Fas 
antibody-induced murine mo- 
dels of apoptosis [25-27]. 
The present study expands 
upon this by describing the 
first application of one of 
these analogues, [18F]WC- 
4-116, to detect in vivo apop-
tosis noninvasively in a 
clinically relevant model of 
ischemia-reperfusion cardio-
vascular disease.
Our quantitative analysis 
of autoradiography, microPET 
imaging, and biodistribution 
study results with [18F]WC-4-
116 consistently demonstrat-
ed that [18F]WC-4-116 accu-
mulates only in at-risk myo- 
cardium regions that have 
increased levels of apoptosis. 
By all three approaches, 
we demonstrated an approxi-
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WC-4-116 can be used to image caspase-3 
activation in this model.
We further confirmed the specificity of [18F]
WC-4-116 for caspase-3 activity by using a 
non-caspase-3 targeted tracer, [18F]ICMT-18, to 
demonstrate that this similarly structured trac-
er did not accumulate in regions of increased 
caspase-3 activity. [18F]ICMT-18 has been used 
in cancer-chemotherapy models as a negative 
control for imaging caspase-3 activation [25]. 
Therefore, we chose to use this approach as 
well because the delivery of a non-targeted, 
structurally similar tracer should depend only 
on blood flow and would best reflect the deliv-
ery of [18F]WC-4-116 but without the effect of 
targeted binding. IR animals imaged with [18F]
ICMT-18 had elevated myocardial caspase-3/7 
activity as expected from the model, but none 
of the quantitative analyses for [18F]ICMT-18 
uptake in ex vivo autoradiography, microPET 
images, and tissues assessed in the biodistri-
bution studies, demonstrated significant [18F]
ICMT-18 accumulation in at-risk myocardial 
regions. Collectively, these lines of evidence 
support the utility of [18F]WC-4-116 to image in 
vivo caspase-3/7 activity specifically in apop-
totic myocardium. These results support fur-
ther study of [18F]WC-116 to images apoptosis 
in vivo.
Prior studies have demonstrated that com-
pared with normal myocardium, the blood flow 
of IR myocardium is diminished [36]. Indeed, 
[15O]H2O microPET imaging confirmed the devel-
opment of significantly reduced regional blood 
flow of the at-risk LV myocardium in the IR but 
not SS animals (see Supplemental Figure 6). 
Thus, our use of [18F]ICMT-18 further enabled 
us to confirm that [18F]WC-4-116 accumulation 
in the IR animals was due to in vivo targeting of 
activated caspases rather than nonspecific 
retention as a result of delayed washout from 
regionally diminished blood flow. Our data dem-
onstrate that at-risk myocardium with con-
firmed increased caspase-3 activation and 
diminished blood flow did not retain [18F]ICMT-
18 more than not-at-risk myocardium, in con-
trast to [18F]WC-4-116, which was retained 
under similar conditions. Therefore, these data 
further strengthen our hypothesis that [18F]
WC-4-116 can be used to detect apoptotic cell 
death in the setting of ischemia-reperfusion 
injury.
One of the primary limitations of this approach 
is the potential lack of sensitivity for detecting 
caspase-3 activation in patients with ischemia 
reperfusion myocardial injury. While our tracer 
may be useful for determining the amount of 
myocardium that could be salvaged after inter-
ventions such as cardiac stenting or bypass 
grafting, we do not have data to know whether 
the tracer can measure clinically significant dif-
ferences in patients. In considering clinical 
applications, the degree of apoptosis in at-risk 
myocardium in patients is in fact not known 
because no tools have been available to 
make such measurements easily in patients. 
Therefore, the development of tools such as 
[18F]WC-4-116 will actually enable investigators 
to begin making such measurements and 
determine whether clinically relevant levels of 
apoptosis can be detected in patients with trac-
ers like [18F]WC-4-116 in patients. Additionally, 
even if the clinical application of [18F]WC-4-116 
is limited, the use of [18F]WC-4-116 in patients 
could still help drive clinical research applica-
tions in which dynamic imaging could be per-
formed for more sophisticated quantitative 
analyses. Conducting clinical trials with this 
tracer will thus best assess the full potential of 
this tracer.
Conclusion
The current studies utilizing the LAD ligation 
model of myocardial IR injury demonstrate that 
the radiolabeled isatin sulfonamide analogue 
[18F]WC-4-116, a functionalized small molecule 
PET tracer specifically targeting the activated 
caspases-3 and -7, is capable of detecting 
increased activity levels of these executioner 
caspases in apoptotic myocardium in vivo. 
Therefore, [18F]WC-4-116 represents a promis-
ing candidate tracer for further translational 
study to detect apoptosis for clinical imaging 
applications.
Acknowledgements
The authors thank the Washington University 
School of Medicine Cyclotron Facility for 18F 
production and the Small Animal Imaging Core 
for conducting the microPET studies. The 
authors would also like to thank Justin Rothfuss 
for his excellent technical assistance. 
Disclosure of conflict of interest
None.
Imaging caspase-3 activity following IR injury
118 Am J Nucl Med Mol Imaging 2016;6(2):110-119
Address correspondence to: Dr. Robert H Mach, 
Department of Radiology, Perelman School of 
Medicine, University of Pennsylvania, Philadelphia, 
PA 19104, USA. Tel: 215-746-8233; Fax: 215-746-
0002; E-mail: rmach@mail.med.upenn.edu 
References
[1] Taylor RC, Cullen SP and Martin SJ. Apoptosis: 
Controlled demolition at the cellular level. Nat 
Rev Mol Cell Biol 2008; 9: 231-241.
[2] Slee EA, Adrain C and Martin SJ. Executioner 
caspase-3, -6, and -7 perform distinct, non-re-
dundant roles during the demolition phase of 
apoptosis. J Biol Chem 2001; 276: 7320-
7326.
[3] Balasubramanian K, Mirnikjoo B and Schroit 
AJ. Regulated externalization of phosphatidyl-
serine at the cell surface. J Biol Chem 2007; 
282: 18357-18364.
[4] Niu G and Chen X. Apoptosis imaging: beyond 
annexin V. J Nucl Med 2010; 51: 1659-1662.
[5] Yang Q, Underwood MJ, Hsin MKY, Liu XC and 
He GW. Dysfunction of pulmonary vascular en-
dothelium in chronic obstructive pulmonary 
disease: Basic considerations for future drug 
development. Curr Drug Metab 2008; 9: 661-
667.
[6] Friedlander RM. Apoptosis and caspases in 
neurodegenerative diseases. N Engl J Med 
2003; 348: 1365-1375.
[7] Narula J, Haider N, Virmani R, DiSalvo TG, 
Kolodgie FD, Hajjar RJ, Schmidt U, Semigran 
MJ, Dec GW and Khaw B-A. Apoptosis in myo-
cytes in end-stage heart failure. N Engl J Med 
1996; 335: 1182-1189.
[8] Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng 
W, Nitahara JA, Quaini E, Di Loreto C, Beltrami 
CA, Krajewski S, Reed JC and Anversa P. Apop-
tosis in the failing human heart. N Engl J Med 
1997; 336: 1131-1141.
[9] Isner JM, Kearney M, Bortman S and Passeri J. 
Apoptosis in human atherosclerosis and reste-
nosis. Circulation 1995; 91: 2703-2711.
[10] Gopal S, Narasimhan U, Day JD, Gao R, Kasper 
EK, Chen C-L, Cina S, Robertson AL and Hruban 
RH. The Quilty lesion enigma: Focal apoptosis/
necrosis and lymphocyte subsets in human 
cardiac allografts. Pathol Int 1998; 48: 191-
198.
[11] Monassier JP. Reperfusion injury in acute myo-
cardial infarction. From bench to cath lab. Part 
I: Basic considerations. Arch Cardiovasc Dis 
2008; 101: 491-500.
[12] Monceau V, Belikova Y, Kratassiouk G, Robidel 
E, Russo-Marie F and Charlemagne D. Myocyte 
apoptosis during acute myocardial infarction in 
rats is related to early sarcolemmal transloca-
tion of annexin A5 in border zone. Am J Physiol 
Heart Circ Physiol 2006; 291: H965-H971.
[13] Holly TA, Drincic A, Byun Y, Nakamura S, Harris 
K, Klocke FJ and Cryns VL. Caspase inhibition 
reduces myocyte cell death induced by myo-
cardial ischemia and reperfusion in vivo. J Mol 
Cell Cardiol 1999; 31: 1709-1715.
[14] Kovacs P, Bak I, Szendrei L, Vecsernyes M, 
Varga E, Blasig IE and Tosaki A. Non-specific 
caspase inhibition reduces infarct size and im-
proves post-ischaemic recovery in isolated 
ischaemic/reperfused rat hearts. Naunyn 
Schmiedebergs Arch Pharmacol 2001; 364: 
501-507.
[15] Chang J, Ormerod M, Powles TJ, Allred DC, Ash-
ley SE and Dowsett M. Apoptosis and prolifera-
tion as predictors of chemotherapy response 
in patients with breast carcinoma. Cancer 
2000; 89: 2145-2152.
[16] Haimovitz-Friedman A, Yang TJ, Thin TH and 
Verheij M. Imaging radiotherapy-induced apop-
tosis. Radiat Res 2012; 177: 467-482.
[17] Zijlstra S, Gunawan J and Burchert W. Synthe-
sis and evaluation of a 18F-labelled recombi-
nant annexin-V derivative, for identification 
and quantification of apoptotic cells with PET. 
Appl Radiat Isot 2003; 58: 201-207.
[18] Blankenberg FG, Katsikis PD, Tait JF, Davis RE, 
Naumovski L, Ohtsuki K, Kopiwoda S, Abrams 
MJ, Darkes M, Robbins RC, Maecker HT and 
Strauss HW. In vivo detection and imaging of 
phosphatidylserine expression during pro-
grammed cell death. Proc Natl Acad Sci U S A 
1998; 95: 6349-6354.
[19] Boersma HH, Kietselaer BLJH, Stolk LML, Ben-
naghmouch A, Hofstra L, Narula J, Heidendal 
GAK and Reutelingsperger CPM. Past, present, 
and future of Annexin A5: From protein discov-
ery to clinical applications. J Nucl Med 2005; 
46: 2035-2050.
[20] Niu G and Chen X. Apoptosis imaging: Beyond 
Annexin V. J Nucl Med 2010; 51: 1659-1662.
[21] Grimberg H, Levin G, Shirvan A, Cohen A, Yo-
gev-Falach M, Reshef A and Ziv I. Monitoring of 
tumor response to chemotherapy in vivo by a 
novel small-molecule detector of apoptosis. 
Apoptosis 2009; 14: 257-267.
[22] Zhao M, Beauregard DA, Loizou L, Davletov B 
and Brindle KM. Non-invasive detection of 
apoptosis using magnetic resonance imaging 
and a targeted contrast agent. Nat Med 2001; 
7: 1241-1244.
[23] Lee D, Long SA, Adams JL, Chan G, Vaidya KS, 
Francis TA, Kikly K, Winkler JD, Sung CM, De-
bouck C, Richardson S, Levy MA, DeWolf WE, 
Keller PM, Tomaszek T, Head MS, Ryan MD, 
Haltiwanger RC, Liang PH, Janson CA, McDevitt 
PJ, Johanson K, Concha NO, Chan W, Abdel-
Meguid SS, Badger AM, Lark MW, Nadeau DP, 
Suva LJ, Gowen M and Nuttall ME. Potent and 
selective nonpeptide inhibitors of caspases 3 
and 7 inhibit apoptosis and maintain cell func-
Imaging caspase-3 activity following IR injury
119 Am J Nucl Med Mol Imaging 2016;6(2):110-119
tionality. J Biol Chem 2000; 275: 16007-
16014.
[24] Chu W, Rothfuss J, Zhou D and Mach RH. Syn-
thesis and evaluation of isatin analogs as cas-
pase-3 inhibitors: Introduction of a hydrophilic 
group increases potency in a whole cell assay. 
Bioorg Med Chem Lett 2011; 21: 2192-2197.
[25] Nguyen QD, Smith G, Glaser M, Perumal M, 
Årstad E and Aboagye EO. Positron emission 
tomography imaging of drug-induced tumor 
apoptosis with a caspase-3/7 specific [18F]-la-
beled isatin sulfonamide. Proc Natl Acad Sci U 
S A 2009; 106: 16375-16380.
[26] Chen DL, Zhou D, Chu W, Herrbrich P, Engle JT, 
Griffin E, Jones LA, Rothfuss JM, Geraci M, 
Hotchkiss RS and Mach RH. Radiolabeled isat-
in binding to caspase-3 activation induced by 
anti-Fas antibody. Nucl Med Biol 2012; 39: 
137-144.
[27] Chen DL, Zhou D, Chu W, Herrbrich PE, Jones 
LA, Rothfuss JM, Engle JT, Geraci M, Welch MJ 
and Mach RH. Comparison of radiolabeled 
isatin analogs for imaging apoptosis with posi-
tron emission tomography. Nucl Med Biol 
2009; 36: 651-658.
[28] Yaoita H, Ogawa K, Maehara K and Maruyama 
Y. Attenuation of ischemia/reperfusion injury 
in rats by a caspase inhibitor. Circulation 1998; 
97: 276-281.
[29] Zhou D, Chu W, Dence CS, Mach RH and Welch 
MJ. Highly efficient click labeling using 2-[18F]
fluoroethyl azide and synthesis of an 18F N-hy-
droxysuccinimide ester as conjugation agent. 
Nucl Med Biol 2012; 39: 1175-1181.
[30] Chen DL, Engle JT, Griffin EA, Miller JP, Chu W, 
Zhou D and Mach RH. Imaging caspase-3 acti-
vation as a marker of apoptosis-targeted treat-
ment response in cancer. Mol Imaging Biol 
2015; 17: 384-393.
[31] Chu W, Rothfuss J, d’Avignon A, Zeng C, Zhou 
D, Hotchkiss RS and Mach RH. Isatin sulfon-
amide analogs containing a Michael addition 
acceptor: a new class of caspase 3/7 inhibi-
tors. J Med Chem 2007; 50: 3751-3755.
[32] Thukkani AK, Martinson BD, Albert CJ, Vogler 
GA and Ford DA. Neutrophil-mediated accumu-
lation of 2-ClHDA during myocardial infarction: 
2-ClHDA-mediated myocardial injury. Am J 
Physiol Heart Circ Physiol 2005; 288: H2955-
H2964.
[33] Su Y, Welch MJ and Shoghi KI. The application 
of maximum likelihood factor analysis (MLFA) 
with uniqueness constraints on dynamic car-
diac microPET data. Phys Med Biol 2007; 52: 
2313.
[34] Herrero P, Kim J, Sharp TL, Engelbach JA, Lew-
is JS, Gropler RJ and Welch MJ. Assessment of 
myocardial blood flow using 15O-water and 
1-11C-acetate in rats with small-animal PET. J 
Nucl Med 2006; 47: 477-485.
[35] Faust A, Wagner S, Law MP, Hermann S, 
Schnockel U, Keul P, Schober O, Schafers M, 
Levkau B and Kopka K. The nonpeptidyl cas-
pase binding radioligand (S)-1-(4-(2-[18F]
Fluoroethoxy)-benzyl)-5-[1-(2-methoxymethyl-
pyrrolidinyl)sulfonyl]isatin ([18F]CbR) as poten-
tial positron emission tomography-compatible 
apoptosis imaging agent. Q J Nucl Med Mol 
Imaging 2007; 51: 67-73.
[36] Ambrosio G, Weisman H, Mannisi J and Becker 
L. Progressive impairment of regional myocar-
dial perfusion after initial restoration of post-
ischemic blood flow. Circulation 1989; 80: 
1846-1861.




HeLa cells were purchased from the Washington University Tissue Culture Support Center and cultured 
in Eagle’s minimum essential medium (MEM) containing 10% heat-inactivated fetal bovine serum (FBS), 
2 mM L-glutamine, 1 × non-essential amino acids (NEAA), and 1 × penicillin/streptomycin solution. 
HeLa cells were maintained in a 5% CO2/95% humidified air atmosphere at 37°C.
In vitro caspase inhibition studies with ICMT-18
Enzyme inhibition assays were performed as previously reported (1). Briefly, recombinant human cas-
pases (3, 6, and 8) and their peptide-specific substrates (Ac-DEVD-AMC, Ac-VEID-AMC, and Ac-IETD-
AMC, respectively) were purchased from Sigma-Aldrich (St. Louis, MO) with the exception of caspase-1 
and caspase-7 which were obtained from BIOMOL Research Laboratories (Plymouth Meeting, PA).
Peptide specific substrates for caspase-1 and -7 (Ac-YVAD-AMC and Ac-DEVD-AMC) were also acquired 
from Sigma-Aldrich. The enzymatic activity of caspases was determined by measuring the accumulation 
of the fluorogenic product 7-amino-4-methylcoumarin (AMC). All assays were prepared in 96-well format 
at a volume of 210 µl per well and consisted of: 100 mM Na+ HEPES (pH 7.4), 10% sucrose, 100 
mMNaCl, 0.1% CHAPS, 5 mM 2-mercaptoethanol, 2 mM EDTA, 10 μM Ac-YVAD-AMC (caspase-1); 20 
mM Na+ HEPES (pH 7.4), 10% sucrose, 100 mMNaCl, 0.1% CHAPS, 2 mM EDTA, 10 μM Ac-DEVD-AMC 
(caspase-3); 20 mM Na+ HEPES (pH 7.4), 10% sucrose, 100 mM NaCl , 0.1% CHAPS, 2 mM EDTA, 10 
μM Ac-VEID-AMC (caspase-6); 20 mM Na+ HEPES (pH 7.4), 100 mM NaCl, 10% sucrose, 0.1% CHAPS, 
5 mM 2-mercaptoethanol, 2 mM EDTA, 10 μM Ac-DEVD-AMC (caspase-7); 20 mM Na+ HEPES (pH 7.4), 
10% sucrose, 100 mM NaCl, 0.1% CHAPS, 2 mM EDTA, 10 μM Ac-IETD-AMC (caspase-8).
Recombinant caspases were first assayed to determine the optimal concentration for each experiment.
Optimal concentrations were based in the linear range of the enzyme activation curves. Peptide inhibi-
tors with known IC50 values were tested together with the compounds as a control for each caspase 
assay.Peptide inhibitors, Ac-DEVD-CHO (caspase-3 and -7), Ac-VEID-CHO (caspase-6), and Ac-IETD-CHO 
(caspase-8) were purchased from Sigma-Aldrich (St. Louis, MO) with exception of caspase-1 specific 
inhibitor (Ac-YVAD-CHO) which was acquired from BIOMOL Research Laboratories (Plymouth Meeting, 
PA). Peptide inhibitors and ICMT-18 were dissolved in DMSO and a serial dilution was performed prior to 
screening in order to obtain desired concentrations. 10 μl was added to each well containing 100 µl 
caspase solution and allowed to incubate on ice for 30 minutes. 100 µl substrate solution was added 
to each well and plates were incubated for 1-2 hours at 37°C. The final concentration of DMSO in all 
wells was 5% of the total volume.
The amount of AMC released was determined by using a Victor3 microplate fluorometer (Perkin Elmer 
Life Sciences, Boston, MA) at excitation and emission wavelengths 355 nm and 460 nm, respectively.
Compounds were tested in duplicate and IC50 curves were calculated for all inhibitors assayed as previ-
ously described [1]. Final IC50’s were the average of 3 independent experiments. The results are depict-
ed in Supplemental Figure 3, Supplementary Materials.
In vitro cold competition cell uptake studies with [18F]WC-4-116 
HeLa cells were plated 2 × 105 cells per well in 12-well plates 24 hours prior to the cell uptake study, 
ensuring 70% confluency of the cells and complete adherence to the plate. Six hours before the initia-
tion of the experiment, 2 μM of staurosporine was added to each well to induce apoptosis and cas-
pase-3 activation. For cold competition studies, 5 μM unlabeled WC-4-116 was first added to selected 
wells prior to the administration of [18F]WC-4-116. At time zero, 1 µCi [18F]WC-4-116 (specific activity, 
5480 mCi/μMol) was added to each well. After incubation of 5, 15, and 30 min the culture medium was 
removed and transferred into 2 ml microcentrifuge tubes for scintigraphic analysis. The cells were then 
washed once with 1 ml of cold phosphate buffered saline; the wash then collected for scintigraphy as 
well. The cells were lysed in the 12-well plates by treatment with 0.2% sodium dodecyl sulfate solution. 
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The cell lysates were harvested and the radioactivity content of the culture medium, wash, and cellular 
lysate were measured using a 1480 Wizard2 gamma counter (Perkin Elmer, Turku, Finland). The assay 
was performed in triplicate and results are reported as counts per min (CPM) of activity in the cell 
lysates for the samples with and without excess (unlabelled) WC-4-116 and depicted in Supplemental 
Figure 4, Supplementary Materials.
Quantitation of at-risk myocardial blood flow of IR and SS animals 
See microPET imaging protocol section in Methods for details. Mean myocardial blood flow ± standard 
errorof the at-risk left ventricular region was assessed by adjunctive [15O]H2O microPET imaging for the 
IR and SS animals prior to the administration of either [18F]WC-4-116 or [18F]ICMT-18. All treatments are 
n = 4 except for the SS group imaged with [18F]WC-4-116 (n = 3), with a p-value (ANOVA) = 0.29 for 
interaction between radiotracer and treatment type. The results are depicted in Supplemental Figure 6, 
Supplementary Materials.
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Supplement Figure 1. The in vivo LAD ligation model produces increased caspase-3 activity and expression. Panel 
A. Mean caspase-3/7 activity (± standard error) is elevated in the at-risk myocardium of the IR animals (n = 5) 
compared with the SS animals (n = 3). B. Western immunoblotting demonstrates enhanced expression of the active 
caspase-3 19 kDa fragment in the at-risk myocardial tissue samples for the IR but not the SS animals. Expression 
of the 35 kDA pro-caspase fragment and GADPH loading control are similar between treatments. AMC and GADPH 
denote amido-4-methylcoumarin and glyceraldehyde 3-phosphate dehydrogenase respectively.
Supplemental Figure 2. Summed images late (left) and early (right) to differentiate tracer uptake in the myocardium 
and in the blood pool.
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Supplemental Figure 3. Inhibition studies of caspases 1, 3, 6, 7, and 8 with ICMT-18. As expected, ICMT displayed 
no inhibition of caspase activity at a concentration up to 100 mM.
Supplemental Figure 4. Blocking studies in staurosporine-treated HeLa cells. Addition of unlabeled WC-4-116 is 
consistent with carrier-added blocking of caspase-3.
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Supplemental Figure 5. Log-scale of TAC to highlight 2-fold ratio between IR and reference region at late time points.
Supplemental Figure 6. [15O]H2O blood flow studies in IR and sham surgery controls. Although the IR animals had 
lower blood flow in the region at risk relative to the sham surgery controls, there was no difference in blood flow 
between the animals receiving [18F]WC-4-116 versus [18F]ICMT-18 (P value = 1.00). These data confirm that the in-
crease uptake of [18F]WC-4-116 versus [18F]ICMT in the region at risk in the IR animals is due to binding to activated 
caspase-3 and not due to differences in myocardial blood flow. 
